Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1353-1357

  Shinchi, H ^a   Maemura, K ^a   Noma, H ^a   Mataki, Y ^a   Aikou, T ^a   Takao, S ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Chemoradiation; Pancreatic cancer; Phase I study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOLOGY; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PANCREAS RESECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; RADIOTHERAPY; SURVIVAL ANALYSIS; TEGAFUR;

EID: 34247617372     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603735     Document Type: Article

References (33)

1. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212
2. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomised trial. J Clin Oncol 15: 2403-2413
3. de Lange SM, van Groeningen CJ, Meijer OW, Cuesta MA, Langendijk JA, van Riel JM, Pinedo HM, Peters GJ, Meijer S, Slotman BJ, Giaccone G (2002) Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 38: 1212-1217
4. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S, Shirasaka T (1998) Preclinical antitumour efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumour xenografts. Int J Oncol 13: 693-698
5. Gastrointestinal Tumour Study Group (1981) Therapy of locally unresectable pancreatic carcinoma: a randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil. Cancer 48: 1705-1710
6. Gastrointestinal Tumour Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751-755
7. Harada K, Kawaguchi S, Supriatno , Onoue T, Yoshida H, Sato M (2004) Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 40: 713-719
8. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumour drug. Clin Cancer Res 5: 2000-2005
9. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumours. Clin Cancer Res 9: 134-142
10. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H (1997) Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79: 1516-1520
11. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H, S-1 Cooperative Study Group (Lung Cancer Working Group) (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939-943
12. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomised comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 3: 373-378
13. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197
14. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28: 219-230
15. McGinn CJ, Zalupski MM (2003) Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys 56(4 Suppl): 10-15
16. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19: 4202-4208
17. Moertel CG, Childs Jr DS, Reitemeier RJ, Colby Jr MY, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2: 865-867
18. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94: 1575-1579
19. Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76: 1671-1677
20. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145
21. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H (2004) Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91: 673-677
22. Paulino AC, Latona C (2000) Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. Cancer Invest 18: 309-313
23. Poen JC, Ford JM, Niederhuber JE (1999) Chemoradiotherapy in the management of localized tumours of the pancreas. Ann Surg Oncol 6: 117-122
24. Schoffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumours. Anticancer Drugs 15: 85-106
25. Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53: 146-150
26. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumour activity in rats. Cancer Res 53: 4004-4009
27. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
28. Takao S, Shinchi H, Sha K, Natsugoe S, Maenohara S, Suenaga T, Nishimata Y, Aikou T (1999) Clinical and biological features of t1 ductal adenocarcinoma of the pancreas. Hepatogastroenterology 46: 498-503
29. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68: 171-178
30. van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumours. J Clin Oncol 18: 2772-2779
31. Whittington R, Neuberg D, Tester WJ, Benson III AB, Haller DG (1995) Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 13: 227-232
32. WHO (World Health Organization) (1980) WHO handbook for reporting results of cancer treatment. Neoplasma 27: 607-619
33. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 221: 721-733